Abstract
Invasive fungal infections are recognized as life-threatening complications primarily in immunocompromised patients, including children with primary immunodeficiencies and hematological malignancies. The antifungal triazoles have become extremely useful components of the antifungal armamentarium. They are well tolerated and possess a broad spectrum of activity. Itraconazole was discovered in 1984 and became available for clinical use in 1990. Itraconazole is a broad spectrum, triazole antifungal agent, and class II drug molecule with low solubility and high permeability and several indications in adults. This article provides a brief overview of the pharmacology of itraconazole with focus on the available data in immunocompromised children and adolescents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
